子宫内膜癌减少淋巴结清扫并优化辅助治疗后的生存结局维持
该研究基于2001–2019年单中心1308例子宫内膜癌患者,评估治疗策略变化对结局的影响。结果显示淋巴结清扫率从78%降至53%,FIGO I期未清扫者3年无复发生存稳定(88% vs 90%,p=0.67)。完全切除的FIGO III期患者辅助化疗从27%升至97%、放疗从57%降至0%,5年总生存和無复发生存改善(p=0.04和p=0.03)。
要点
- 淋巴结清扫率从78%降至53%,淋巴结转移检出率维持稳定(9% vs 8%,p=0.58)。
- FIGO I期未行淋巴结清扫者3年无复发生存稳定(88% vs 90%,p=0.67)。
- 完全切除的FIGO III期患者辅助化疗增加、放疗减少,5年生存改善。
核心结论
- 术前影像与组织学分层可使淋巴结清扫率降至约50%而不增加3年复发。
- 辅助化疗单独用于完全切除的FIGO III期患者生存不劣于含放疗方案,晚期可能更优。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2001–2019年Haukeland大学医院初治子宫内膜癌患者1308例。
- 比较停止辅助放疗和个体化淋巴结清扫前后的临床结局。
主要发现
- 淋巴结清扫率从2001–2012年的78%降至2013–2019年的53%。
- 淋巴结转移检出率维持稳定(9% vs 8%,p=0.58)。
- FIGO I期未清扫者3年无复发生存稳定(88% vs 90%,p=0.67)。
- 完全切除的FIGO III期患者辅助化疗从27%升至97%,放疗从57%降至0%(p<0.001)。
- FIGO III期患者5年总生存HR 0.49 [95%CI 0.37–0.65] vs 0.61 [0.45–0.83],p=0.04;无复发生存HR 0.51 [0.39–0.68] vs 0.71 [0.60–0.85],p=0.03。
关键数值与推荐
- FIGO I期未行淋巴结清扫者3年无复发生存88% vs 90%(p=0.67)。
- 完全切除的FIGO III期患者5年总生存HR 0.49 [95%CI 0.37–0.65] vs 0.61 [0.45–0.83],p=0.04。
- 完全切除的FIGO III期患者5年无复发生存HR 0.51 [0.39–0.68] vs 0.71 [0.60–0.85],p=0.03。
临床怎么用
- 可依据术前影像和组织学评估个体化缩小淋巴结清扫范围。
- 完全切除的FIGO III期患者可考虑以辅助化疗替代辅助放疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Main controversies in endometrial cancer treatment include the role of lymphadenectomy and optimal adjuvant treatment. We assessed clinical outcome in a population-based endometrial cancer cohort in relation to changes in treatment management over two decades. METHODS: All consenting endometrial cancer patients receiving primary treatment at Haukeland University Hospital from 2001 to 2019 were included (n = 1308). Clinicopathological variables were evaluated for year-to-year changes. Clinical outcome before and after discontinuing adjuvant radiotherapy and individualizing extent of lymphadenectomy was analyzed. RESULTS: The rate of lymphadenectomy was reduced from 78% in 2001-2012 to 53% in 2013-2019. The rate of patients with verified lymph node metastases was maintained (9% vs 8%, p = 0.58) and FIGO stage I patients who did not undergo lymphadenectomy had stable 3-year recurrence-free survival (88% vs 90%, p = 0.67). Adjuvant chemotherapy for completely resected FIGO stage III patients increased from 27% to 97% from 2001 to 2009 to 2010-2019, while adjuvant radiotherapy declined from 57% to 0% (p < 0.001). These patients had improved 5-year overall- and recurrence-free survival; 0.49 [95% CI: 0.37-0.65] in 2001-2009 compared to 0.61 [0.45-0.83] in 2010-2019, p = 0.04 and 0.51 [0.39-0.68] to 0.71 [0.60-0.85], p = 0.03, respectively. For stage I, II and IV, survival rates were unchanged. CONCLUSIONS: Our study demonstrates that preoperative stratification by imaging and histological assessments permits a reduction in lymphadenectomy to around 50%, and is achievable without an increase in recurrences at 3 years. In addition, our findings support that adjuvant chemotherapy alone performs equally to adjuvant radiotherapy with regard to survival, and is likely superior in advanced stage patients.
引用
- Forsse D, Berg HF, Bozickovic O, et al. Maintained survival outcome after reducing lymphadenectomy rates and optimizing adjuvant treatment in endometrial cancer. Gynecol Oncol. 2020. PMID: 33317908. doi:10.1016/j.ygyno.2020.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。